- Home
- DRMA vs LGHL Comparison
DRMA vs LGHL Comparison
Compare DRMA & LGHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DRMA | LGHL |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 2.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DRMA | LGHL |
|---|---|---|
| Price | $2.16 | $3.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 101.5K | ★ 764.5K |
| Earning Date | 11-14-2025 | 04-30-2024 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.13 | $3.32 |
| 52 Week High | $23.70 | $213.20 |
Technical Indicators
Market Signals| Indicator | DRMA | LGHL |
|---|---|---|
| Relative Strength Index (RSI) | 30.68 | 49.44 |
| Support Level | $2.13 | $3.32 |
| Resistance Level | $2.98 | $3.81 |
| Average True Range (ATR) | 0.25 | 1.12 |
| MACD | -0.03 | -0.31 |
| Stochastic Oscillator | 5.84 | 1.72 |
Price Performance
Historical ComparisonAbout DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About LGHL Lion Group Holding Ltd.
Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.